MedTrace Logo

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

NCT02633111 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 501

Last updated 2025-11-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin lymphoma. The purpose of the study is to see if MRD in blood samples can potentially replace CT scans after completion of chemotherapy in the future.

Conditions

  • B-cell Non-Hodgkin Lymphoma
  • Aggressive

Interventions

OTHER

collected at pre-treatment tumor biopsy

to identify the tumor-specific clonotype

OTHER

Peripheral blood tests

for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).

DEVICE

PET/CT

at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)

Sponsors & Collaborators

Principal Investigators

  • Anita Kumar, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02633111 on ClinicalTrials.gov